At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 34,412 enrolled
Drug / intervention
Cervarix +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Effectiveness of Two Vaccination Strategies Using GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
In Brief
A Phase 4 clinical trial evaluating Cervarix and Engerix-B for Infections, Papillomavirus. Completed, enrolled 34,412 participants across 6 sites.
Detailed Summary
Genital infections with oncogenic human papillomaviruses (HPV) are common in both men and women. The most important disease associated with oncogenic HPV infection is cervical cancer, currently the second leading cause of cancer-related death among women globally. The current study is designed to evaluate the overall impact of HPV immunization in adolescents 12-15 years of age.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Papillomavirus
CountriesFinland
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2007
Enrollment StartOct 2007
Primary CompletionDec 2014
TodayJul 2026
First PostedSep 26, 2007
Enrollment StartOct 4, 2007
Primary CompletionDec 17, 2014
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 18.8 years ago
Interventions
Cervarixbiological
Intramuscular injection, 3 doses
Engerix-Bbiological
Intramuscular injection, 3 doses